Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours

•The impact of sex differences in oncological systemic therapies is still unknown.•There is a lack of evidence specially in neuroendocrine tumorstumours (NET).•We study impact of sex in multikinase inhibitors toxicity in NETs in five clinical trials.•We found nine toxicities which were more frequent in female patients, and two more common in male patients.•Those differences could impact individualisation of systemic treatment.